RFC
BCRX icon

Regions Financial Corp’s BioCryst Pharmaceuticals BCRX Stock Holding History

Regions Financial Corp’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,363
Closed -$213K – 910
2021
Q4 		$213K Buy
+15,363
New +$203K ﹤0.01% 869
2019
Q2 		– Sell
-2,400
Closed -$20K – 913
2019
Q1 		$20K Hold
2,400
– – ﹤0.01% 1357
2018
Q4 		$19K Buy
+2,400
New +$18.7K ﹤0.01% 1362

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Regions Financial Corp's BCRX Position: Q1 2022 in Review

Regions Financial Corp sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2022, closing a stake of 15,363 shares — an estimated $213K sold.

Regions Financial Corp first reported a position in BCRX in Q4 2018 and held it in 3 quarters. The position peaked at $213K in Q4 2021. 233 funds tracked by Wall St. Rank hold BCRX as of Q1 2022.

  • Regions Financial Corp reported no remaining BioCryst Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Regions Financial Corp sold 15,363 BioCryst Pharmaceuticals shares in Q1 2022, an estimated $213K.
  • Regions Financial Corp first reported a position in BioCryst Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Regions Financial Corp's BioCryst Pharmaceuticals position peaked at $213K in Q4 2021.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2022.

Based on Regions Financial Corp's 13F filing for Q1 2022, filed 25 Apr 2022.